Sanofi-Aventis to Acquire U.S. Biopharma Firm

Sanofi-Aventis (Paris) says it has signed an agreement to acquire TargeGen (San Diego, CA), a privately held biopharmaceutical company developing small molecule kinase inhibitors for the treatment of certain forms of leukemia, lymphoma and other hematological malignancies and blood disorders. Sanofi-Aventis will make an upfront payment of $75 million upon closing of the transaction, and further milestones payments at different stages of development of TargeGen lead product TG 101348. The total payments, including the upfront payment, could reach $560 million. The...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers